GLP‑1: genes and a pill

Glucagon-like peptide 1 is a gut hormone your body releases after you eat, and weight-loss drugs copy that signal to slow stomach emptying and turn down hunger. Semaglutide is one of those drugs, and tirzepatide adds a second gut-hormone signal on top of that. (nature.com) That same signal is why two people can take the same dose and get very different results. Some lose large amounts of weight, while others stop early because nausea, vomiting, or diarrhea hit hard enough to make the drug hard to stay on. (scientificamerican.com) A new study looked for one reason by scanning the DNA of nearly 28,000 people who reported taking a glucagon-like peptide 1 drug for weight loss. The dataset came from 23andMe participants, and the analysis linked common gene variants to both weight-loss response and stomach side effects. (nature.com) One variant sat near the gene for the glucagon-like peptide 1 receptor, which is the molecular “lock” these drugs are designed to fit. People carrying that variant tended to lose more weight, which is a clue that tiny inherited changes in the drug’s target can shift how strongly the medicine works. (nature.com) Another signal showed up near a gene tied to a different gut hormone called peptide YY, which also helps control appetite and digestion. In the study, variants in that region were linked to a higher chance of nausea and other gastrointestinal side effects. (scientificamerican.com) The genes did not explain everything. Scientific American reports the variants accounted for only part of the spread in outcomes, which means dose, diet, other medicines, health conditions, and plain chance still shape what happens on these drugs. (scientificamerican.com) While that paper was landing, the Food and Drug Administration approved Foundayo, Eli Lilly’s once-daily oral form of orforglipron, for chronic weight management. The agency said the decision came 50 days after filing under its Commissioner’s National Priority Voucher pilot program. (fda.gov) Foundayo is not semaglutide, but it goes after the same glucagon-like peptide 1 pathway in pill form instead of a weekly shot. That makes it a direct new option for people who want the appetite effects of this drug class without using an injection pen. (fda.gov) (ajmc.com) The pill arrives only a few months after Novo Nordisk’s oral Wegovy, which uses semaglutide, reached the United States market in January 2026. That means the weight-loss market now has two oral glucagon-like peptide 1 options where it used to be dominated by injectable brands like Wegovy and Zepbound. (ajmc.com) (cnbc.com) Put together, the week’s news points in two directions at once: more choice in how these drugs are taken, and better clues about who will benefit most or feel sickest. The next step is not just making more glucagon-like peptide 1 drugs, but matching the right one to the right patient before months of trial and error. (nature.com) (fda.gov)